Results
Strides Q2 Revenue Up 17% YoY, EBITDA Crosses ₹2.5B
Strides Pharma Q2FY27 revenue grew 17.1% YoY to ₹14,297m, driven by 31% growth in Ex-US markets which surpassed US revenue.
EBITDA increased 8.4% YoY to ₹2,509m, crossing ₹2,500m quarterly for the fir
